drugset / Trial / NCT02763787
Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate the safety and tolerability of single oral rising doses of BIA 3-202 up to 800 mg (proposed doses 10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg) in groups of 9 healthy male adult subjects, to characterise the preliminary pharmacokinetics of single rising oral doses of BIA 3-202 in healthy male adult subjects, to investigate the effects of single doses of BIA 3-202 on COMT activity in human erythrocytes and to investigate the effect of food on the pharmacokinetics of a single dose of BIA 3-202.
Timeline
- Start
- 2000-04
- Primary completion
- 2000-06
- Completion
- 2000-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nebicapone | Small molecule | 10 mg | Oral |
| Subject | Nebicapone | Small molecule | 30 mg | Oral |
| Subject | Nebicapone | Small molecule | 50 mg | Oral |
| Subject | Nebicapone | Small molecule | 100 mg | Oral |
| Subject | Nebicapone | Small molecule | 200 mg | Oral |
| Subject | Nebicapone | Small molecule | 400 mg | Oral |
| Subject | Nebicapone | Small molecule | 800 mg | Oral |